Telephus gets patents for superbug battling antibodies

By Gareth Macdonald contact

- Last updated on GMT

Telephus gets patents for superbug battling antibodies

Related tags: Monoclonal antibody

Australia has granted Telephus Medical a patent for an antibody that targets superbugs, including MRSA.

The patent covers the science that underpins its methicillin-resistant Staphylococcus aureus (MRSA) targeting monoclonal antibody, TPH 101.

The monoclonal antibody is designed to both treat and prevent infection by binding the endo-β-N-acetylglucosaminidase (Gmd) subunit of staphylococcal autolysin, which is the enzyme that allows Staphylococci ​to attach to tissues and form biofilms.

In animal studies the antibody was shown to accelerate bacterial clearance and inhibit bacterial growth.

California, US-based Telephus licensed the antibody from a laboratory at New York’s University of Rochester (UR) run by company founder and chief scientific officer (CSO), Edward Schwarz.

Telephus – which is named after an ancient Greek warrior whose wounds only healed thanks to Odysseus’s medical intervention – licensed intellectual property (IP) covering wider therapeutic use of neutralizing antibodies to treat infection.

The Australian patent follow a few weeks after authorities in Canada and Japan issued Telephus with patents for the same antibody.

CEO Mark Benedyk said: “This third patent in our intellectual property estate extends Telephus’ portfolio covering monoclonal antibody compositions and methods targeting antibiotic-resistant bacteria.

He added that: “It also describes the technology on which our initial product, TPH 101, is based.”

In 2013, San Diego-headquartered Telephus told Xconomy it had raised $1.4m from individual investors and the Wilson Sonsini law firm and said it planned to take the drug into Phase I trials in 2016​.

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars